Compare DPRO & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DPRO | BNR |
|---|---|---|
| Founded | 1998 | 2014 |
| Country | Canada | China |
| Employees | N/A | N/A |
| Industry | Aerospace | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.7M | 252.7M |
| IPO Year | 2019 | 2019 |
| Metric | DPRO | BNR |
|---|---|---|
| Price | $6.64 | $18.77 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $15.67 | N/A |
| AVG Volume (30 Days) | ★ 1.9M | 16.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $42.16 | $136.32 |
| Revenue Next Year | $145.52 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.63 | $2.18 |
| 52 Week High | $14.37 | $41.72 |
| Indicator | DPRO | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 46.34 | 35.76 |
| Support Level | $6.23 | $7.99 |
| Resistance Level | $7.15 | $24.23 |
| Average True Range (ATR) | 0.50 | 1.98 |
| MACD | 0.03 | -0.57 |
| Stochastic Oscillator | 40.92 | 26.12 |
Draganfly Inc is a Canada based company. It is engaged in the provision of engineering services and the manufacture of commercial unmanned vehicle systems and software. The company operates in Canada, the United States, and Internationally. The three segments are Drones, Vital (Vital Intelligence), and Corporate. The Drones segment derives its revenue from products and services related to the sale of unmanned aerial vehicles (UAV). The Vital segment derives its revenue from the sale of products that measure vitals to help detect symptoms from large groups of people from a distance. The Corporate segment includes all costs not directly associated with the Drone and Vital segments. It generates majority of its revenue from Drones segment.
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.